Duffy antigen inhibitors: Useful therapeutics for malaria?

Trends in Parasitology

Volumn 26, Issue 7, 2010, Pages 329-333

  Handel, Tracy M ^a   Horuk, Richard ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISININ; ATOVAQUONE; CHEMOKINE RECEPTOR AGONIST; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHLOROQUINE; DUFFY BINDING PROTEIN; MEFLOQUINE; PRIMAQUINE; PYRIMETHAMINE; SULFADOXINE; CELL SURFACE RECEPTOR; CHEMOKINE; DUFFY ANTIGEN BINDING PROTEIN, PLASMODIUM; PARASITE ANTIGEN; PROTOZOAL PROTEIN;

ARTICLE; BINDING ASSAY; BLOCKING FACTOR; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PLASMODIUM VIVAX MALARIA; PROTEIN BINDING; ANIMAL; ANTAGONISTS AND INHIBITORS; HUMAN; IMMUNOLOGY; MALARIA, VIVAX; PARASITOLOGY; PLASMODIUM VIVAX;

ANIMALS; ANTIGENS, PROTOZOAN; CHEMOKINES; HUMANS; MALARIA, VIVAX; PLASMODIUM VIVAX; PROTOZOAN PROTEINS; RECEPTORS, CELL SURFACE;

PLASMODIUM VIVAX;

EID: 77953959495     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2010.03.010     Document Type: Article

References (39)

1. Mendis K., et al. The neglected burden of Plasmodium vivax malaria. Am. J. Trop. Med. Hyg. 2001, 64:97-106.
2. Price R.N., et al. Vivax malaria: neglected and not benign. Am. J. Trop. Med. Hyg. 2007, 77:79-87.
3. Ridley R.G. Medical need, scientific opportunity and the drive for antimalarial drugs. Nature 2002, 415:686-693.
4. Galinski M.R., Barnwell J.W. Plasmodium vivax: who cares?. Malar J. 2008, 7(Suppl. 1):S9.
5. Desowitz R.S. The malaria vaccine: seventy years of the great immune hope. Parassitologia 2000, 42:173-182.
6. Bejon P., et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N. Engl. J. Med. 2008, 359:2521-2532.
7. Haynes J.D., et al. Receptor-like specificity of a Plasmodium knowlesi malarial protein that binds to Duffy antigen ligands on erythrocytes. J. Exp. Med. 1988, 167:1873-1881.
8. Miller L.H., et al. Erythrocyte receptors for (Plasmodium knowlesi) malaria: Duffy blood group determinants. Science 1975, 189:561-563.
9. Horuk R., et al. A receptor for the malarial parasite Plasmodium vivax: the erythrocyte chemokine receptor. Science 1993, 261:1182-1184.
10. Rot A. Contribution of Duffy antigen to chemokine function. Cytokine Growth Factor Rev. 2005, 16:687-694.
11. Pruenster M., et al. Duffy antigen-receptor for chemokines transports chemokines and supports their pro-migratory activity. Nat. Immunol. 2008, 10:101-108.
12. Hesselgesser J., et al. A mutant of melanoma growth stimulating activity does not activate neutrophils but blocks erythrocyte invasion by malaria. J. Biol. Chem. 1995, 270:11472-11476.
13. Chitnis C.E., et al. The domain on the Duffy blood group antigen for binding Plasmodium vivax and P. knowlesi malarial parasites to erythrocytes. J. Exp. Med. 1996, 184:1531-1536.
14. Singh S.K., et al. Structural basis for Duffy recognition by the malaria parasite Duffy-binding-like domain. Nature 2006, 439:741-744.
15. Ranjan A., Chitnis C.E. Mapping regions containing binding residues within functional domains of Plasmodium vivax and Plasmodium knowlesi erythrocyte-binding proteins. Proc. Natl. Acad. Sci. USA 1999, 96:14067-14072.
16. Doms R.W., Peiper S.C. Unwelcomed guests with master keys: how HIV uses chemokine receptors for cellular entry. Virology 1997, 235:179-190.
17. Dorr P., et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 2005, 49:4721-4732.
18. Liu R., et al. Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection. Cell 1996, 86:367-377.
19. Lim J.K., et al. CCR5: no longer a 'good for nothing' gene--chemokine control of West Nile virus infection. Trends Immunol. 2006, 27:308-312.
20. Miller L.H., et al. The resistance factor to Plasmodium vivax in blacks. The Duffy-blood- group genotype, FyFy. N. Engl. J. Med. 1976, 295:302-304.
21. Tournamille C., et al. Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals. Nat. Genet. 1995, 10:224-228.
22. Peiper S.C., et al. The Duffy antigen/receptor for chemokines (DARC) is expressed in endothelial cells of Duffy negative individuals who lack the erythrocyte receptor. J. Exp. Med. 1995, 181:1311-1317.
23. Reutershan J., et al. DARC on RBC limits lung injury by balancing compartmental distribution of CXC chemokines. Eur. J. Immunol. 2009, 39:1597-1607.
24. Bandyopadhyay S., et al. Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression. Nat. Med. 2006, 12:933-938.
25. Baird J.K. Effectiveness of antimalarial drugs. N. Engl. J. Med. 2005, 352:1565-1577.
26. Ryan J.R., et al. Evidence for transmission of Plasmodium vivax among a duffy antigen negative population in Western Kenya. Am. J. Trop. Med. Hyg. 2006, 75:575-581.
27. Dorn C.P., et al. Antagonists of the human CCR5 receptor as anti-HIV-1 agents. part 1: discovery and initial structure-activity relationships for 1 -amino-2-phenyl-4-(piperidin-1-yl)butanes. Bioorg. Med. Chem. Lett. 2001, 11:259-264.
28. Finke P.E., et al. Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2, structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes. Bioorg. Med. Chem. Lett. 2001, 11:265-270.
29. Chitnis C.E., Miller L.H. Identification of the erythrocyte binding domains of Plasmodium vivax and Plasmodium knowlesi proteins involved in erythrocyte invasion. J. Exp. Med. 1994, 180:497-506.
30. Choe H., et al. Sulphated tyrosines mediate association of chemokines and Plasmodium vivax Duffy binding protein with the Duffy antigen/receptor for chemokines (DARC). Mol. Microbiol. 2005, 55:1413-1422.
31. Hans D., et al. Mapping binding residues in the Plasmodium vivax domain that binds Duffy antigen during red cell invasion. Mol. Microbiol. 2005, 55:1423-1434.
32. Grimberg B.T., et al. Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein. PLoS Med. 2007, 4:e337.
33. Kocken C.H., et al. Transgenic Plasmodium knowlesi: relieving a bottleneck in malaria research?. Trends Parasitol. 2009, 25:370-374.
34. Horuk R., et al. A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection. J. Biol. Chem. 2001, 276:4199-4204.
35. Van den Eede P., et al. Human Plasmodium knowlesi infections in young children in central Vietnam. Malar. J. 2009, 8:249.
36. Putaporntip C., et al. Differential prevalence of Plasmodium infections and cryptic Plasmodium knowlesi malaria in humans in Thailand. J. Infect. Dis. 2009, 199:1143-1150.
37. Cox-Singh J., et al. Severe malaria - a case of fatal Plasmodium knowlesi infection with post-mortem findings: a case report. Malar. J. 2010, 9:10.
38. Doranz B.J., et al. A dual-tropic primary HIV-1 isolate that uses fusin and the b-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996, 85:1149-1158.
39. Chitnis C.E., Sharma A. Targeting the Plasmodium vivax Duffy-binding protein. Trends Parasitol. 2008, 24:29-34.